Why the study?
Does bivalirudin reduce bleeding complications and adverse clinical events compared to unfractionated heparin in adult patients undergoing PCI?
Does bivalirudin reduce bleeding complications and adverse clinical events compared to unfractionated heparin in adult patients undergoing PCI?
In a real-world cohort of patients undergoing PCI, bivalirudin significantly reduced major bleeding and post-catheterization myocardial infarctions compared to unfractionated heparin without compromising efficacy.
No takes yet. Share an insight, caveat, or question.
Associated with reduced major bleeding in PCI; leaves open preference over UFH pending randomized confirmation.
Watson et al. (2007) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: